ТОНИЗИРУЮЩИЕ (ЭНЕРГЕТИЧЕСКИЕ) НАПИТКИ: ОСНОВНЫЕ КОМПОНЕНТЫ, ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ

Скачать статью в PDF
Номер журнала: 
10
Год издания: 
2016

Р. Ханферьян, доктор медицинских наук, профессор Федеральный исследовательский центр питания, биотехнологии и безопасности пищи, Москва E-mail: khanferyan@ion.ru

Представлены современные данные об уровне потребления энергетических напитков, фармакокинетике и фармакодинамике основных компонентов напитков – кофеина и таурина, а также результаты исследования по безопасности входящих в состав энергетических напитков биологически активных компонентов.

Ключевые слова: 
энергетические напитки
кофеин
таурин
диетические добавки
безопасность

Для цитирования
Ханферьян Р. ТОНИЗИРУЮЩИЕ (ЭНЕРГЕТИЧЕСКИЕ) НАПИТКИ: ОСНОВНЫЕ КОМПОНЕНТЫ, ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ . Врач, 2016; (10): 72-76


It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Scientific Opinion on the safety of caffeineEFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) // EFSA J. – 2015; 13 (5): 4102.
  2. Dorfman L., Jarvik M. Comparative stimulant and diuretic actions of caffeine and theobromine in man // Clin. Pharmacol. Ther. – 1970; 11 (6): 869–72.
  3. Boothby W., Rowntree L. Drugs and basal metabolism // J. Pharmacol. Exp. Ther. – 1924; 22: 99–108.
  4. Haldi J., Bachmann G., Ensor C. et al. The effects of various amounts of caffeine on the gaseous exchange and the respiratory quotient in man // J. Nutr. – 1941; 21: 307.
  5. Miller D., Stock M., Stuart J. The effects of caffeine and carnitine on the oxygen consumption of fed and fasted subjects // Proc. Nutr. Soc. – 1974; 33: 28
  6. A.Acheson K., Zahorska-Markiewicz B. Pittet Ph. et al. Caffeine and coffee their influence on metabolic rate and substrate utilization in normal weight and obese individuals // Am. J. Clin. Nutr. – 1980; 33 (5): 989–97.
  7. Nathanson J. Caffeine and related methylxanthines: possible naturally occurring pesticides // Science. – 1984; 226 (4671): 184–7.
  8. Mathavan S., Premalatha Y., Christopher M. Effects of caffeine and theophylline on the fecundity of four lepidopteran species // Exp Biol. – 1985; 44 (2): 133–8.
  9. Hollingsworth R., Armstrong J., Campbell E. Caffeine as a repellent for slugs and snails // Nature. – 2002; 417: 915–6.
  10. Barone J., Roberts H. Caffeine consumption // Food Chem. Toxicol. – 1996; 34: 119–29.
  11. Juliano L., Griffiths R. A critical review of caffeine withdrawal: Empirical validation of symptoms and signs, incidence, severity, and associated features // Psychopharmacology. – 2004; 176: 1–29.
  12. Drewnowski A., Rehm C. Sources of caffeine in diets of US children and adults: trends by beverage type and purcgase location // Nutrients. – 2016; 8: 154–66.
  13. Калинин А.Я. Кофеин – друг или враг? // Компетентность. – 2014; 9–10 13. (120–121): 43–51.
  14. Бессонов В.В., Ханферьян Р.А. Кофеин в питании. Сообщение I. Поступление с питанием и регулирование // Вопр. питания. – 2015; 4: 119–27.
  15. Fredholm B., B15. ättig K., Holmén J. et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use // Pharmacol. Rev. – 1999; 51 (1): 83–133.
  16. Magkos F., Kavouras S. Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action // Crit. Rev. Food Sci. Nutr. – 2005; 45: 535–62.S.
  17. Teekachunhatean N., Tosri N., Rojanasthien S. et al. Pharmacokinetics of Caffeine following a Single Administration of Coffee Enema versus Oral Coffee Consumption in Healthy Male Subjects // ISRN Pharmacology. – 2013; Article ID 147238. http://dx.doi.org/10.1155/2013/147238
  18. Perera V., Gross A., McLachlan A. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma // Biomed. Chromatogr. – 2010; 24 (10): 1136–44.
  19. Kamimori G., Karyekar C., Otterstetter R. et al. The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers // Inter. J. Pharm. – 2002; 234 (1–2): 159–76
  20. Fredholm B., B20. ättig K., Holmén J. et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use // Pharmacol. Rev. – 1999; 51 (1): 83–133.
  21. Arnaud M. The pharmacology of caffeine // Prog. Drug Res. – 1987; 31: 21. 273–313.
  22. Schneider H., Ma L., Glatt H. Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry // J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. – 2003; 789 (2): 227–37.
  23. Kot M., Daniel W. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat // Pharmacol. Rep. – 2008; 60 (6): 789–97.
  24. Gonzalez A., Hoffman J., Wells A. et al. Effects of Time-Release Caffeine Containing Supplement on Metabolic Rate, Glycerol Concentration and Performance // J. Sports Sci. Med. – 2015; 14 (2): 322–32.
  25. Astrup A., Breum L., Toubro S. et al. The effect and safety of an ephedrine/ caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial // Int. J. Obes. Relat. Metab. Disord. – 1992; 16 (4): 269–77.
  26. Huxtable R. Physiological actions of taurine // Physiolog. Rev. – 1992; 72 26. (1): 101–63.
  27. SchafferS. W., ItoT, Azuma J. Clinical significance of taurine // Amino 27. Acids. – 2014; 46 (1): 1–5.
  28. De Luca A., Pierno S., Conte Camerino D. Taurine: the appeal of a safe 28. amino acid for skeletal muscle disorders // J. Transl. Med. – 2015; 13: 243.
  29. Faggiano A., Melis D., Alfieri R. et al. Sulfur amino acids in Cushing’s 29. disease: insight in homocysteine and taurine levels in patients with active and cured disease // J. Clin. Endocrinol. Metab. – 2005; 90: 6616–22.
  30. Sturman J. Taurine in development // J. Nutr. – 1988; 118: 1169–76.30.
  31. Jansson T. Amino acid transporters in the human placenta // Pediatr. 31. Res. – 2001; 49: 141–7.
  32. Tappaz M. Taurine biosynthetic enzymes and taurine transporter: 32. molecular identification and regulations // Neurochemical. Research. – 2004; 29 (1): 83–96.
  33. Ramamoorthy S., Leibach F., Mahesh V. et al. Functional characterization 33. and chromosomal localization of a cloned taurine transporter from human placenta // Biochem. J. – 1994; 300: 893–900.
  34. Norberg S., Powell T., Jansson T. Intrauterine growth restriction is 34. associated with a reduced activity of placental taurine transporters // Pediatr. Res. – 1998; 44: 233–8.
  35. Na-Young Lee, Young-Sook Kang.mailto:yskang@sookmyung.ac.kr Regulation of taurine transport at the blood-placental barrier by calcium ion, PKC activator and oxidative stress conditions // J. Biomed. Sci. – 2010; 17 (Suppl. 1): 37
  36. Imae M., Asano T., Murakami S. Potential role of taurine in the prevention of diabetes and metabolic syndrome // Amino Acids. – 2014; 46 (1): 81–8.
  37. Ripps H., Shen W. Review: taurine: a “very essential” amino acid // Molecular Vision. – 2012; 18: 2673–86.
  38. Ito T., Schaffer S., Azuma J. The potential usefulness of taurine on diabetes mellitus and its complications // Amino Acids. – 2012; 42 (5): 1529–39.
  39. Hayes K., Carey R., Schmidt S. Retinal degeneration associated with taurine deficiency in the cat // Science. – 1975; 188 (4191): 949–51.
  40. Zeng K., Xu H., Mi M. et al. Effects of taurine on glial cells apoptosis and taurine transporter expression in retina under diabetic conditions // Neurochemical Research. – 2010; 35 (10): 1566–74.
  41. Hansen S. The role of taurine in diabetes and the development of diabetic complications // Diabet. Metab. Res. Rev. – 2001; 17 (5): 330–46.
  42. Di Leo M., Santini S., Cercone S. et al. Chronic taurine supplementation ameliorates oxidative stress and Na+ K+ ATPase impairment in the retina of diabetic rats // Amino Acids. – 2002; 23 (4): 401–6.
  43. Di Leo M., Ghirlanda G., Gentiloni Silveri N. et al. Potential therapeutic effect . of antioxidants in experimental diabetic retina: a comparison between chronic taurine and vitamin E plus selenium supplementations // Free Radical Research. – 2003; 37 (3): 323–30.
  44. Han X., Patters A., Jones D. et al. The taurine transporter: mechanisms of regulation // Acta Physiologica. – 2006; 187 (1–2): 61–73.
  45. Franconi F., Miceli M., Fazzini A. et al. Taurine and diabetes. Humans and experimental models. In Advances in Experimental Medicine and Biology / New York, NY, USA: Springer, 1996; 579–82.
  46. Franconi F., Loizzo A., Ghirlanda G. et al. Taurine supplementation and diabetes mellitus // Curr. Opin. Clin. Nutr. Metab. Care. – 2006; 9 (1): 32–6.
  47. Baynes J., Thorpe S. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm // Diabetes. – 1999; 48 (1): 1–9.
  48. Napol Z., Seghieri G., Bianchi L. et. al. Taurine Transporter Gene Expression in Mononuclear Blood Cells of Type 1 Diabetes Patients // J. Diabetes Res. – 2016: 7313162. Published online 2016 Feb 3.
  49. Проскурякова Т.В., Шохонова В.А., Анохин П.К. и др. Безалкогольные 49. кофеинсодержащие тонизирующие напитки: экспериментальное исследова-ние // Наркология. – 2015; 2: 18–30.